REFRACTORY MULTIPLE MYELOMA

This study tests a combination of drugs (selinexor, pomalidomide, dexamethasone, and sometimes carfilzomib) in people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combo controls the ca…

This study tests a drug called trametinib in 50 patients whose cancers have a specific genetic change called an NF1 mutation. The drug blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing.

This study tests a drug called ipatasertib in people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink…

This study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…

This study tests a drug called afatinib in people with advanced cancers (excluding certain lung cancers) or lymphomas that have a specific change in the EGFR gene. The drug blocks signals that make cancer cells grow. The goal is to see if it can shrink or slow tumors in patients …

This study tested the drug crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink or stop the growth of these tumors. Only 5 patients took part, and the study is no longer enrolling new…

This study tests a drug called osimertinib in people with advanced cancers that have specific EGFR gene mutations. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or slow the disease. The trial includes 19 adults with vario…

This study tests a drug called MLN0128 (TAK-228) in 35 adults with advanced cancers that have a specific genetic change (mTOR mutation). The drug works by blocking certain enzymes that cancer cells need to grow. The main goal is to see if the drug can shrink or stop the cancer fr…

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF gene mutations or fusions. The goal was to see if trametinib could shrink tumors or stop them from growing by blocking certain proteins. The trial is no longer recruiting, and results…

This study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…

This study was designed to test the safety and best dose of an experimental oral drug called GB1211 (Selvigaltin) when added to standard chemotherapy for people with multiple myeloma that has come back or stopped responding. The drug works by blocking a protein linked to inflamma…

This study tests a combination of four drugs (selinexor, bortezomib, dexamethasone, and daratumumab) in 62 adults with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in cancer. Because …

This early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find a safe dose and see if the combination can control the ca…

This study tests a combination of four drugs (isatuximab, carfilzomib, pomalidomide, and dexamethasone) in 30 people whose multiple myeloma has returned or stopped responding to earlier treatments. The goal is to see how many patients' tumors shrink or disappear. This is not a cu…

This study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that haven't responded to other treatments…

This study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…

This study looked at whether taking lenalidomide (a drug that helps the immune system fight cancer) after a stem cell transplant can keep multiple myeloma from coming back longer than taking a placebo. About 460 people with active multiple myeloma took part. The goal was to see h…

This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or stopped responding after previous treatment with daratumumab. The goal is to see if this combo can shrink tumors mo…

This study tests a drug called AZD1775 in people with advanced cancers that have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with various solid tum…

This early-phase trial tests a personalized cell therapy (CAR T) that targets a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has returned or not responded to at least three prior treatments. The main goal is to check safety and find the right dose…

This study tests a drug called larotrectinib in 35 people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors or stop the cancer from sprea…

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced or hard-to…

This study tests two targeted drugs, dabrafenib and trametinib, in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a BRAF V600 mutation. The drugs block proteins that help cancer grow. The goal is to see if the combination can shrink tumors or stop them …

This study tests a drug called copanlisib in 35 adults with advanced or treatment-resistant cancers that have a specific change in the PTEN gene. The drug blocks a faulty protein that helps cancer cells grow. The goal is to see if it can shrink tumors or stop them from growing fo…

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. About 49 participants will receive the drug to see if it can shrink tum…

This study is for people with advanced cancers that have a specific genetic change called an NF2 mutation. The drug defactinib blocks a protein that may help these cancers grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults are t…

This study tests the drug crizotinib in people with advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib works by blocking signals that help cancer cells grow and spread. The main goal…

This study tests a drug called taselisib in 70 people with advanced cancers (except breast cancer) that have a specific genetic change called PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors …

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. The drug works by blocking signals that make cancer cells grow. The goal is to see if the tumors shrink or stop growing. About 10 adults with various cancers (but not…

This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug ca…

This study tests a drug called crizotinib in 20 adults with advanced cancers that have a specific genetic change called MET exon 14 deletion. The drug works by blocking enzymes that help cancer cells grow and spread. Researchers want to see if it can shrink tumors or stop them fr…

This study tests a drug called GSK2636771 in people whose cancers have lost a gene called PTEN. The drug blocks a protein (PI3K-beta) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing. About 35 adults with advanced…

This study tested the drug trametinib in 4 people with advanced cancers that have GNAQ or GNA11 mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing.

This early-stage trial tests a new drug called CB-839 HCl combined with two standard treatments (carfilzomib and dexamethasone) for multiple myeloma that has returned or stopped responding to prior therapy. The main goals are to find the safest dose and to see how well the combin…

This early-phase trial tests a new treatment for multiple myeloma that has returned or not responded to prior therapies, including BCMA-targeting treatments. The approach combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and …

This study tests a drug called binimetinib in 53 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NRAS mutation. The drug blocks proteins that help cancer grow. The main goal is to see if the drug can shrink tumors or stop…

This study tests a drug called ulixertinib in 35 adults with advanced cancers that have certain BRAF gene changes (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. The main goal is to see how many patients' tumors shrink or disappear. This i…

This study tests a drug called GSK2636771 in 24 adults with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growin…

This study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial includes patients with various advanced solid tumors, lymphoma, or multiple myeloma that have not respond…

This study explores whether using lab tests that screen many drugs at once, along with genetic information, can help doctors choose the best treatment for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. The goal is to see i…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study looks at how doctors in Italy currently treat a tough type of multiple myeloma that doesn't respond to the three main drug classes. Researchers will collect information from medical records of about 250 patients to see how well treatments work in real life and what the…